U.S. markets close in 1 hour 44 minutes

Aclaris Therapeutics, Inc. (ACRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.4500-0.0600 (-1.33%)
As of 2:08PM EDT. Market open.

Aclaris Therapeutics, Inc.

640 Lee Road
Suite 200
Wayne, PA 19087
United States
484 324 7933

Full Time Employees75

Key Executives

NameTitlePayExercisedYear Born
Dr. Neal S. Walker D.O.Co-Founder, CEO, Pres & Director715.5kN/A1970
Mr. Frank RuffoCo-Founder, CFO & Treasurer510.89kN/A1966
Dr. David N. GordonChief Medical Officer529.07kN/A1969
Ms. Kamil Ali-Jackson Esq., J.D.Co-Founder, Chief Legal Officer, Chief Compliance Officer & Sec.N/AN/A1959
Dr. Michael Steven Tung M.D.Sr. VP of Corp. Strategy/Investor RelationsN/AN/A1974
Ms. Sheila KennedyVP of MarketingN/AN/AN/A
Mr. Kevin ScottVP of SalesN/AN/AN/A
Mr. Jeffrey WayneInterim Head of CommercialN/AN/AN/A
Dr. Joseph MonahanExec. VP of R&DN/AN/AN/A
Mr. Gary DeCrescenzoSr. VP of Pharmaceutical R&DN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.

Corporate Governance

Aclaris Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.